Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children

Front Immunol. 2023 Dec 20:14:1327875. doi: 10.3389/fimmu.2023.1327875. eCollection 2023.

Abstract

Primary COVID-19 vaccination for children, 5-17 years of age, was offered in the Netherlands at a time when a substantial part of this population had already experienced a SARS-CoV-2 infection. While vaccination has been shown effective, underlying immune responses have not been extensively studied. We studied immune responsiveness to one and/or two doses of primary BNT162b2 mRNA vaccination and compared the humoral and cellular immune response in children with and without a preceding infection. Antibodies targeting the original SARS-CoV-2 Spike or Omicron Spike were measured by multiplex immunoassay. B-cell and T-cell responses were investigated using enzyme-linked immunosorbent spot (ELISpot) assays. The activation of CD4+ and CD8+ T cells was studied by flowcytometry. Primary vaccination induced both a humoral and cellular adaptive response in naive children. These responses were stronger in those with a history of infection prior to vaccination. A second vaccine dose did not further boost antibody levels in those who previously experienced an infection. Infection-induced responsiveness prior to vaccination was mainly detected in CD8+ T cells, while vaccine-induced T-cell responses were mostly by CD4+ T cells. Thus, SARS-CoV-2 infection prior to vaccination enhances adaptive cellular and humoral immune responses to primary COVID-19 vaccination in children. As most children are now expected to contract infection before the age of five, the impact of infection-induced immunity in children is of high relevance. Therefore, considering natural infection as a priming immunogen that enhances subsequent vaccine-responsiveness may help decision-making on the number and timing of vaccine doses.

Keywords: B cells; COVID-19 vaccine; SARS-CoV-2; T cells; adaptive; antibodies; children; infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BNT162 Vaccine
  • CD8-Positive T-Lymphocytes
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Immunity, Humoral*
  • SARS-CoV-2
  • Vaccination

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding for this study was provided by the Dutch Ministry of Health, Welfare and Sport.